Vericel Corp (VCEL)
47.83
-0.05
(-0.10%)
USD |
NASDAQ |
May 03, 16:00
47.81
-0.02
(-0.04%)
After-Hours: 20:00
Vericel Enterprise Value: 2.200B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 2.200B |
| May 02, 2024 | 2.203B |
| May 01, 2024 | 2.164B |
| April 30, 2024 | 2.106B |
| April 29, 2024 | 2.144B |
| April 26, 2024 | 2.114B |
| April 25, 2024 | 2.085B |
| April 24, 2024 | 2.117B |
| April 23, 2024 | 2.132B |
| April 22, 2024 | 2.082B |
| April 19, 2024 | 2.003B |
| April 18, 2024 | 2.008B |
| April 17, 2024 | 2.124B |
| April 16, 2024 | 2.185B |
| April 15, 2024 | 2.242B |
| April 12, 2024 | 2.204B |
| April 11, 2024 | 2.243B |
| April 10, 2024 | 2.265B |
| April 09, 2024 | 2.321B |
| April 08, 2024 | 2.316B |
| April 05, 2024 | 2.357B |
| April 04, 2024 | 2.325B |
| April 03, 2024 | 2.369B |
| April 02, 2024 | 2.366B |
| April 01, 2024 | 2.445B |
| Date | Value |
|---|---|
| March 28, 2024 | 2.402B |
| March 27, 2024 | 2.417B |
| March 26, 2024 | 2.284B |
| March 25, 2024 | 2.205B |
| March 22, 2024 | 2.155B |
| March 21, 2024 | 2.145B |
| March 20, 2024 | 2.100B |
| March 19, 2024 | 2.094B |
| March 18, 2024 | 2.024B |
| March 15, 2024 | 2.028B |
| March 14, 2024 | 2.025B |
| March 13, 2024 | 2.040B |
| March 12, 2024 | 2.035B |
| March 11, 2024 | 2.044B |
| March 08, 2024 | 2.073B |
| March 07, 2024 | 2.055B |
| March 06, 2024 | 2.072B |
| March 05, 2024 | 2.037B |
| March 04, 2024 | 2.052B |
| March 01, 2024 | 2.049B |
| February 29, 2024 | 2.096B |
| February 28, 2024 | 2.199B |
| February 27, 2024 | 2.208B |
| February 26, 2024 | 2.212B |
| February 23, 2024 | 2.176B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
256.14M
Minimum
Mar 18 2020
3.060B
Maximum
Jun 28 2021
1.355B
Average
1.321B
Median
Feb 28 2023
Enterprise Value Benchmarks
| ANI Pharmaceuticals Inc | 1.506B |
| Arbutus Biopharma Corp | 362.27M |
| Chimerix Inc | -97.70M |
| Karyopharm Therapeutics Inc | 109.50M |
| Y-mAbs Therapeutics Inc | 673.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 12.99M |
| Revenue (Quarterly) | 65.00M |
| Total Expenses (Quarterly) | 52.26M |
| EPS Diluted (Quarterly) | 0.27 |
| Gross Profit Margin (Quarterly) | 74.63% |
| Profit Margin (Quarterly) | 19.99% |
| Earnings Yield | -0.17% |
| Normalized Earnings Yield | -0.1673 |